Profound Medical Posts 104% Revenue Growth, Secures Humana Coverage for TULSA Procedure
Event summary
- Profound Medical reported Q1 2026 revenue of $5.3M, up 104% YoY, with $2.5M from recurring revenue and $2.9M from capital equipment sales.
- The company's TULSA-PRO installed base reached 80 systems, with 6 additional systems shipped in Q1 2026.
- Humana became the first national payer in the U.S. to cover the TULSA Procedure, adding 6.9M covered lives.
- Profound announced superiority on the primary safety endpoint in the CAPTAIN trial comparing TULSA Procedure to robotic radical prostatectomy.
- The company projects full-year 2026 revenue of $25M, representing 56% growth compared to 2025.
The big picture
Profound Medical's strong Q1 2026 results highlight the growing adoption of its TULSA Procedure, particularly with the recent payer coverage from Humana. The company's focus on expanding payer access and securing clinical validation through trials positions it to challenge the current standard of care in prostate cancer treatment. The medical device industry is increasingly valuing non-invasive, MRI-guided therapies, and Profound's technologies align with this trend, potentially expanding its market reach beyond prostate cancer to other conditions requiring tissue ablation.
What we're watching
- Revenue Growth Trajectory
- Whether Profound can sustain its triple-digit revenue growth throughout 2026, given the company's full-year guidance of $25M.
- Payer Expansion
- The pace at which Profound can secure additional payer coverage for the TULSA Procedure, following Humana's coverage.
- Clinical Validation
- How additional clinical outcomes from the CAPTAIN trial will impact the adoption of the TULSA Procedure as a standard of care.
Related topics